NCT04251533 2026-04-03
EPIK-B3
Novartis
Phase 3 Terminated
Clinical Trials
10 trialsNCT04967248 2025-12-04
A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting
Novartis
Terminated
NCT03284957 2025-11-24
AMEERA-1
Sanofi
Phase 1/2 Terminated
NCT04216472 2025-09-30
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04899349 2024-10-09
EPIK-B4
Novartis
Phase 2 Terminated
NCT05966584 2024-08-29
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT04862143 2024-06-20
TELEPIK
Novartis
Phase 2 Terminated
NCT03386162 2022-11-28
SAFIR-PI3K
UNICANCER
Phase 2 Terminated
NCT02734615 2022-08-01
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
Novartis
Phase 1 Terminated
NCT01708161 2018-09-13
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
Novartis
Phase 1/2 Terminated